Arcutis Biotherapeutics, Inc. ARQT ARQ-234 program costs — R&D

Other product segments

Similar metrics at other companies

SRRKRD Expense Srk181 — Research And Development Expense

$36K-96.8%

SRRKRD Expense Srk439 — Research And Development Expense

$1.76M-58.9%

AXSMAZD7325 — Research And Development Expense

$2.3M—

TNGXTNG456Direct Program Expenses-RD — Research And Development Expense

$2.06M+55.8%

BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)

$3.97M+30.4%

BCRXAvoralstat — Research and Development Expense (Excluding Acquired in Process Cost)

$893K-64.0%

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s ARQ-234 program costs — R&D?

Arcutis Biotherapeutics, Inc. (ARQT) reported ARQ-234 program costs — R&D of $11M in Q1 2026.

What does ARQ-234 program costs — R&D mean?

This metric represents the direct research and development expenditures specifically allocated to the advancement of the ARQ-234 clinical program. It captures the costs associated with preclinical studies, clinical trial execution, and regulatory development activities for this specific therapeutic candidate. Tracking these costs allows investors to assess the capital intensity and progress of the company's pipeline assets as they move through the drug development lifecycle.